biotech · Fabry Disease (X-linked lysosomal storage disease). · Kidney Transplant Rejection · SGMO
SANGAMO THERAPEUTICS
SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS clinical programs — 25 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 7000 Marina Blvd, Brisbane, California 94005, US
- Founded
- 1995
- Employees
- 266
- Programs
- 25
- Drugs
- 14
- Patents
- 192
SANGAMO THERAPEUTICS projects
25 ClinicalTrials.gov programs sponsored by SANGAMO THERAPEUTICS.
SANGAMO THERAPEUTICS has 25 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
TX200-TR101
SANGAMO THERAPEUTICS, INC
Kidney Transplant Rejection
1 trial -
CERE-110: Adeno-Associated Virus injection Surgery
SANGAMO THERAPEUTICS, INC
Alzheimer's Disease
1 trial -
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
SANGAMO THERAPEUTICS, INC
Idiopathic Parkinson's Disease
1 trial -
CERE-120: Adeno-Associated Virus Delivery of Neurturin
SANGAMO THERAPEUTICS, INC
Idiopathic Parkinson's Disease
1 trial -
Plerixafor
SANGAMO THERAPEUTICS, INC
Sickle Cell Disease
1 trial -
SB-318
SANGAMO THERAPEUTICS, INC
MPS I
1 trial -
SB-509
SANGAMO THERAPEUTICS, INC
Diabetes Mellitus, Type 1
4 trials -
SB-509
SANGAMO THERAPEUTICS, INC
Amyotrophic Lateral Sclerosis
1 trial -
SB-728-T
SANGAMO THERAPEUTICS, INC
HIV
2 trials -
SB-728mR-T
SANGAMO THERAPEUTICS, INC
Human Immunodeficiency Virus (HIV)
1 trial -
SB-913
SANGAMO THERAPEUTICS, INC
Mucopolysaccharidosis II
1 trial -
ST-400 Investigational product
SANGAMO THERAPEUTICS, INC
Transfusion Dependent Beta-thalassemia
1 trial -
ST-503
SANGAMO THERAPEUTICS, INC
Chronic Neuropathic Pain
1 trial -
ST-920
SANGAMO THERAPEUTICS, INC
Fabry Disease
1 trial -
ST-920
SANGAMO THERAPEUTICS, INC
Fabry Disease (X-linked lysosomal storage disease).
1 trial -
ST-920
SANGAMO THERAPEUTICS, INC
Fabry Disease (X-linked lysosomal storage disease).
1 trial -
TX200-TR101
SANGAMO THERAPEUTICS, INC
Kidney Transplant Rejection
1 trial -
TX200-TR101
SANGAMO THERAPEUTICS, INC
Prophylaxis against renal transplant rejection
1 trial -
CERE-110: Adeno-Associated Virus Delivery of NGF
SANGAMO THERAPEUTICS, INC
Alzheimer's Disease
1 trial -
CERE-120: AAV2-NTN
SANGAMO THERAPEUTICS, INC
Parkinson's Disease
1 trial -
SB-728-T
SANGAMO THERAPEUTICS, INC
HIV Infection
1 trial -
SB-728mR-HSPC Infusion 3 days following busulfan conditioning
SANGAMO THERAPEUTICS, INC
HIV
1 trial -
SB-FIX
SANGAMO THERAPEUTICS, INC
Hemophilia B
1 trial -
ZFN modified T cells
SANGAMO THERAPEUTICS, INC
HIV
1 trial -
hVEGF-A
SANGAMO THERAPEUTICS, INC
Diabetic Neuropathy
1 trial
Frequently asked questions
How many clinical projects does SANGAMO THERAPEUTICS have?
25 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.